{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menieres-disease/prescribing-information/cinnarizine/","result":{"pageContext":{"chapter":{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine","depth":2,"htmlHeader":"<!-- begin field f6755452-5b97-4684-b3f5-d75c9144af1e --><h2>Cinnarizine</h2><!-- end field f6755452-5b97-4684-b3f5-d75c9144af1e -->","summary":"","htmlStringContent":"<!-- begin item d9cf737d-9a06-4640-9cf5-791a070b4af4 --><!-- end item d9cf737d-9a06-4640-9cf5-791a070b4af4 -->","topic":{"id":"c2b20ab8-7e5a-5868-9804-8a9d6a2cb567","topicId":"193a65ca-1981-44e6-a5d3-781aa5010b2c","topicName":"Meniere's disease","slug":"menieres-disease","lastRevised":"Last revised in November 2017","chapters":[{"id":"16b06288-e565-5867-9311-37b626851eb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47494f3b-a0fd-53b2-8613-2cd38f1a11dd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"371c2958-24a9-5d9c-ae14-b7539d491674","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d13d990c-bded-5655-aa70-40268a150cbd","slug":"changes","fullItemName":"Changes"},{"id":"c184f0c8-2419-565f-ab73-a1a5591fc29d","slug":"update","fullItemName":"Update"}]},{"id":"9c1b726a-8066-5632-89ef-7764e1edd1d3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8ee08c5c-67dd-57f0-b666-7d874024d8ed","slug":"goals","fullItemName":"Goals"},{"id":"7fd84935-e76b-56af-b285-b58ed2a8ecc2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"981ad1f7-1003-50fc-8e49-411ea1ff34d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4307ba4c-2b7b-54c0-9103-71e4a18f16ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"416a0198-b8a8-5272-8684-3aa5a380fc74","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2221f812-317a-569e-a4bc-0183f833d0f7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"272bf558-6edb-531a-a2d4-4b19639383ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25e37eb8-40b6-5b11-b9d3-4fe5378e1524","slug":"definition","fullItemName":"Definition"},{"id":"65d7cb18-66af-5447-8401-2c8e24d64dd4","slug":"cause","fullItemName":"Cause"},{"id":"4f2a2237-790f-5b99-9650-34b58a75512e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ed8dbd0f-7c6b-53bf-a2b9-77006586ab7e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a4342e8b-12e6-56d8-a716-190cac3ce652","slug":"complications","fullItemName":"Complications"},{"id":"5b357eed-7df9-57ca-9c0d-0511ecf6f601","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"318e7c3d-c3c6-5a60-be9d-9179e643d3fb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0ae90882-dae2-56da-b987-8bca0eefb6b3","slug":"suspecting-menieres-disease","fullItemName":"Suspecting Meniere's disease"},{"id":"7fc93a60-260c-5030-a14e-d6375907f198","slug":"making-a-diagnosis","fullItemName":"Making a diagnosis"},{"id":"73c5b8af-f846-541f-a7d9-48e2c6b9679c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","fullItemName":"Management","slug":"management","subChapters":[{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2054a7c4-97a4-57e7-a3de-05ea67cfa502","slug":"betahistine","fullItemName":"Betahistine"},{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"5de25a19-1810-510b-ba6b-c9b9979fb4c6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f893c00d-a15b-572d-8042-6164f0ee4141","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"18f58ee1-0ff6-5c45-b4a3-5f2f22070e03","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"41de5190-f85f-57eb-81a1-fa4aad3af7b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e4161b0-4719-5539-99e5-e094855a17d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5a5f7056-1236-5638-904d-dce7e2b843af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b63dcde-7589-5a5a-b219-7f2ff2e0b527","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a8e9bf2-d409-5815-8467-31e3a6379930","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"3bc99635-5d56-5079-9336-c63b8a549489","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 9804717c-a6a3-4968-b673-a81000ef0e31 --><h3>What dosage of cinnarizine should I prescribe?</h3><!-- end field 9804717c-a6a3-4968-b673-a81000ef0e31 -->","summary":"","htmlStringContent":"<!-- begin item 81c9ef9f-6456-479e-bf3f-a81000ef0beb --><!-- begin field 29de3d09-a9dd-4586-bbb2-a81000ef0e31 --><ul><li>For vestibular symptoms, prescribe oral cinnarizine 30 mg three times a day. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 29de3d09-a9dd-4586-bbb2-a81000ef0e31 --><!-- end item 81c9ef9f-6456-479e-bf3f-a81000ef0beb -->","subChapters":[]},{"id":"83774328-27f3-5e5c-976c-6e3ba16a0eab","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 59be0055-0793-42cc-a19f-a81000ef2c3a --><h3>What are the contraindications and cautions when prescribing cinnarizine?</h3><!-- end field 59be0055-0793-42cc-a19f-a81000ef2c3a -->","summary":"","htmlStringContent":"<!-- begin item 512f43c3-035c-4c79-9691-a81000ef2a26 --><!-- begin field 10398996-fb6f-42f5-bcc8-a81000ef2c3a --><ul><li>Do not prescribe cinnarizine if the person: <ul><li>Is hypersensitive to cinnarizine or any of its excipients.</li><li>Has porphyria.</li><li>Has severe liver disease (there is an increased risk of coma).</li></ul></li><li>Prescribe cinnarizine with caution if the person has:<ul><li>Parkinson’s disease — give only if the advantages outweigh the risk of disease exacerbation.</li><li>Hepatic or renal impairment.</li><li>Epilepsy.</li><li>Prostatic hypertrophy.</li><li>Pyloroduodenal obstruction.</li><li>Susceptibility to angle closure glaucoma.</li><li>Urinary retention.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 10398996-fb6f-42f5-bcc8-a81000ef2c3a --><!-- end item 512f43c3-035c-4c79-9691-a81000ef2a26 -->","subChapters":[]},{"id":"43f93f57-d395-5d0b-9b6f-2c3b5881ac90","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 67f77453-4661-4637-b3b0-a81000ef4e60 --><h3>What are the adverse effects of cinnarizine?</h3><!-- end field 67f77453-4661-4637-b3b0-a81000ef4e60 -->","summary":"","htmlStringContent":"<!-- begin item 1977a410-f461-4cee-b286-a81000ef4c65 --><!-- begin field 661ac80a-3138-40a3-bfcb-a81000ef4e60 --><ul><li>Adverse effects of cinnarizine are more common in older people and include drowsiness, nausea, dyspepsia, and weight gain.</li><li>Less common adverse effects include:<ul><li>Anaphylaxis, angio-oedema.</li><li>Dyskinesia, extrapyramidal disorder, Parkinsonism, tremor, convulsions.</li><li>Cholestatic jaundice.</li><li>Palpitations.</li><li>Bronchospasm.</li><li>Subacute cutaneous lupus erythematosus, lichen planus, photosensitivity reactions, rashes.</li><li>Angle-closure glaucoma.</li><li>Confusion, depression.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 661ac80a-3138-40a3-bfcb-a81000ef4e60 --><!-- end item 1977a410-f461-4cee-b286-a81000ef4c65 -->","subChapters":[]},{"id":"054aff2a-4588-5a54-b0fd-b20494f146cc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 035aac4e-58dc-4e91-8431-a81000ef6bd6 --><h3>What drug interactions occur with cinnarizine?</h3><!-- end field 035aac4e-58dc-4e91-8431-a81000ef6bd6 -->","summary":"","htmlStringContent":"<!-- begin item 6060cef1-2d66-4a58-b050-a81000ef6a5a --><!-- begin field 3af58637-1ef6-4aab-bd38-a81000ef6bd6 --><ul><li>Concurrent use of cinnarizine and alcohol, CNS depressants, or tricyclic antidepressants may result in increased sedative effects. Advise that this may influence the ability to perform skilled tasks such as driving.</li><li>The use of phenelzine in conjunction with cinnarizine increases the risk of antimuscarinic adverse effects.</li><li>Avoid using cinnarizine within 4 days of skin testing as it may influence the results. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>] </p><!-- end field 3af58637-1ef6-4aab-bd38-a81000ef6bd6 --><!-- end item 6060cef1-2d66-4a58-b050-a81000ef6a5a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}